Antiangiogenic drugs in oncology: a focus on drug safety and the elderly - a mini-review

Gerontology
S BoehmM Joerger

Abstract

Angiogenesis is essential for normal tissue and even more so for solid malignancies. At present, inhibition of tumor angiogenesis is a major focus of anticancer drug development. Bevacizumab, a humanized antibody against VEGF, was the first antiangiogenic agent to be approved for advanced non-small cell lung cancer, breast cancer and colorectal cancer. The most commonly observed adverse events are hypertension, proteinuria, bleeding and thrombosis. Sunitinib, a small molecule blocking intracellular VEGF, KIT, Flt3 and PDGF receptors, which regulate angiogenesis and cell growth, is approved for the treatment of advanced renal cell cancer (RCC) and malignant gastrointestinal stromal tumor. The most frequent adverse events include hand-foot syndrome, stomatitis, diarrhea, fatigue, hypothyroidism and hypertension. Sorafenib, an oral multikinase inhibitor, is approved for the second-line treatment of advanced RCC and upfront treatment of advanced hepatocellular carcinoma. Most common adverse events with sorafenib are dermatologic (hand-foot skin reaction, rash, desquamation), fatigue, diarrhea, nausea, hypothyroidism and hypertension. More recently, cardiovascular toxicity has increasingly been recognized as a potential adverse even...Continue Reading

Citations

Sep 20, 2011·International Journal of Clinical Oncology·Yoshinori HoshinoYuko Kitagawa
Nov 26, 2011·Targeted Oncology·Gaetan des GuetzJean-François Morère
Aug 28, 2012·The Oncologist·José A Serra-RexachMiguel Martín
Aug 18, 2010·Cancer Metastasis Reviews·Elvira Gonzalez de Mejia, Vermont P Dia
Jan 31, 2012·Gastroenterology Research and Practice·Renato CannizzaroPaola Spessotto
Mar 31, 2012·Evidence-based Complementary and Alternative Medicine : ECAM·Saswati MahapatraKrishna Vanaja Donkena
Oct 10, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Isamu OkamotoKazuhiko Nakagawa
Jan 10, 2012·The American Journal of the Medical Sciences·Jessica M FleagleCarl E Freter
Dec 31, 2015·Current Urology Reports·Tania González León, Maricela Morera Pérez
Feb 7, 2012·Cancer Treatment Reviews·Ahmad AwadaLouis Chow
Mar 13, 2012·Revue des maladies respiratoires·C Clément-DuchêneY Martinet
Apr 2, 2016·Proceedings of the National Academy of Sciences of the United States of America·Yin ZhangYihai Cao
May 28, 2013·Journal of Hepatology·Rita GolfieriUNKNOWN European Network on Radioembolization with Yttrium-90 Microspheres (ENRY) study collaborators
Mar 26, 2015·Future Oncology·Ahmed El Kaffas, Gregory J Czarnota
Feb 28, 2014·The Korean Journal of Internal Medicine·Seon Ha BaekKwon-Wook Joo
Sep 12, 2014·International Journal of Nephrology·Hassan Izzedine
Dec 21, 2013·Critical Reviews in Oncology/hematology·Rim S IshakFadi S Farhat
Mar 3, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Sandra FeldtMartin Schulz
May 10, 2012·Technology in Cancer Research & Treatment·Ahmed El KaffasGregory J Czarnota
Jun 27, 2019·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J FeliuM J Molina-Garrido

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
A TempletonS Gillessen
© 2022 Meta ULC. All rights reserved